Prostate Cancer - Results from #19620

Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond - Abstract October 1, 2014

Prostate cancer screening recommendations have little effect October 1, 2014

Cabazitaxel-a next-generation taxane for the treatment of patients with metastatic castration-resistant prostate cancer - Abstract September 30, 2014

89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer - Abstract September 30, 2014

Prostate cancer antigen-3 (PCA3) and PCA3-based nomograms in the diagnosis of prostate cancer: An external validation of Hansen's nomogram on a Norwegian cohort - Abstract September 30, 2014

Association of anesthesia technique for radical prostatectomy with biochemical recurrence: A retrospective cohort study - Abstract September 30, 2014

Long-term intra-fractional motion of the prostate using hydrogel spacer during Cyberknife® treatment for prostate cancer - a case report - Abstract September 30, 2014

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: - Abstract September 30, 2014

Smoking and risk of low- and high-grade prostate cancer: Results from the REDUCE study - Abstract September 30, 2014

Radiation-induced secondary malignancy in prostate cancer: A systematic review and meta-analysis - Abstract September 30, 2014

Lower urinary tract symptoms and their severity in men subjected to prostate biopsy - Abstract September 30, 2014

Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria - Abstract September 29, 2014

Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: A pilot study - Abstract September 29, 2014

ZYTIGA® plus prednisone demonstrates statistically significant overall survival after 49-month follow-up analysis in chemotherapy-naïve men with metastatic castration-resistant prostate cancer September 29, 2014

Abiraterone acetate (ZYTIGA®)-development and literature review - Abstract September 29, 2014

Extraprostatic extension of prostatic carcinoma: Is its proximity to surgical margin or Gleason score important? - Abstract September 29, 2014

#ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) September 27, 2014

#ESMO14 - Poster: Long-term cellular response and variables correlating with humoral response in STAND, a randomised phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer September 27, 2014

Bayer and Orion initiate phase III trial of novel prostate cancer agent ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer September 27, 2014

Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer - Abstract September 26, 2014

Page 982 of 1436